? The goal of this proposal is to develop and validate a process for generating in vitro, gene expression assays for toxicology. Specifically, we propose to derive gene signatures, that can classify chemicals according to specific liver pathology endpoints, using whole genome expression profiling in rat primary hepatocytes in vitro and to convert the gene signatures into efficient, high throughput, validated assays for use as a cost efficient, fast screening tool. The project will utilize the joint expertise of Iconix researchers in identifying toxicological gene signatures using compound treatment and global, microarray gene expression analysis, and Althea researchers for translating these signatures into high throughput gene expression assays using highly multiplexed, universal-primed rtPCR (UP-rtPCR). In this Phase I proposal, we intend to demonstrate the process for one general hepatoxicity endpoint, Cholestatis, and one general toxicity endpoint, DNA damage. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43CA110876-01
Application #
6841043
Study Section
Special Emphasis Panel (ZCA1-SRRB-U (M1))
Program Officer
Song, Min-Kyung H
Project Start
2004-09-01
Project End
2007-02-28
Budget Start
2004-09-01
Budget End
2007-02-28
Support Year
1
Fiscal Year
2004
Total Cost
$97,654
Indirect Cost
Name
Iconix Pharmaceuticals, Inc.
Department
Type
DUNS #
018099247
City
Mountain View
State
CA
Country
United States
Zip Code
94043